{"id":17586,"date":"2016-06-20T12:13:20","date_gmt":"2016-06-20T11:13:20","guid":{"rendered":"http:\/\/www.asperbio.com\/?page_id=17586"},"modified":"2019-08-27T11:29:28","modified_gmt":"2019-08-27T08:29:28","slug":"glaukoom","status":"publish","type":"page","link":"https:\/\/www.asperbio.com\/et\/asper-ophthalmics-testid\/glaukoom\/","title":{"rendered":"Glaukoom"},"content":{"rendered":"

Glaukoomiga seotud geenide sekveneerimine<\/span><\/h2>\n
\n\n\n\n
Geenid:<\/strong><\/td>\nACVR1, ASB10, BEST1, CANT1, COL18A1, CYP1B1, FOXC1, LMX1B, LOXL1, LTBP2, MYOC, NTF4, OPTN, PAX6, PITX2, PITX3, SBF2, SLC4A4, WDR36<\/em><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n
\n\n\n\n
Metoodika:<\/strong><\/td>\nKodeeriva piirkonna sekveneerimine (NGS).
\nKoopiaarvu muutuste bioinformaatiline anal\u00fc\u00fcs (CNV). CNV leidude kinnitamine teise meetodiga toimub lisaanal\u00fc\u00fcsina, vastavalt hinnakirjale.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n
\n\n\n\n
Testi valmimisaeg:<\/strong><\/td>\n6-9 n\u00e4dalat<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n
\n\n\n\n
N\u00f5uded proovi-
\nmaterjalile:<\/strong><\/td>\n		2-4 ml t\u00e4isverd antikoagulandiga EDTA (lilla korgiga katsuti)<\/p>\n

1\u00a0\u00b5g DNA-d elueerituna TE, AE puhvris v\u00f5i steriilses vees, kontsentratsiooniga 100-250 ng\/\u00b5l
\nDNA saata toatemperatuuril v\u00f5i k\u00fclmutatuna. A260\/A280 suhe peaks olema 1.8-2.0. DNA peab agaroosgeelis olema detekteeritav \u00fche tervikliku b\u00e4ndina.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\n\n\n\n
Tellimine:<\/strong><\/td>\nProovimaterjal saata koos saatekirjaga<\/a><\/strong><\/span> Asper Biogene laborisse<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n
\n<\/div>\n

N\u00e4idustused geenitesti tegemiseks<\/b>:<\/p>\n

1. Kliinilise diagnoosi kinnitamine
\n2.\u00a0Kandluse m\u00e4\u00e4ramine riskigruppi kuuluvatel pereliikmetel
\n3.\u00a0Geneetiline n\u00f5ustamine<\/p>\n

Glaukoom<\/strong> on silmahaigus, mille korral n\u00e4gemisn\u00e4rvi kahjustus v\u00f5ib p\u00f5hjustada progresseeruvat n\u00e4gemise halvenemist ja pimedust. Enamikel glaukoomi juhtudel on n\u00e4gemisn\u00e4rvi kahjustus tingitud silma siser\u00f5hu t\u00f5usust. Sagedasemad glaukoomi t\u00fc\u00fcbid on avatud<\/strong>– ja kinnise nurga glaukoom<\/strong>.<\/p>\n

Normaalr\u00f5huga glaukoomi<\/strong> korral v\u00f5ivad n\u00e4gemisn\u00e4rvi kahjustus ja vaatev\u00e4lja ahenemine esineda ka normaalsete silma siser\u00f5hu v\u00e4\u00e4rtuste juures.<\/p>\n

Glaukoom avaldub tavaliselt vanemas eas. Varajases eas glaukoomi teke on tavaliselt seotud p\u00e4rilike faktoritega. Kaasas\u00fcndinud glaukoom<\/strong> v\u00f5ib kaasneda m\u00f5ne muu haigusega, p\u00f5hjuseks on silma vesivedeliku \u00e4ravoolukanalite struktuursed anomaaliad. Kaasas\u00fcndinud glaukoom on s\u00fcnnihetkel avaldunud ning diagnoositakse harilikult esimese eluaasta jooksul.<\/p>\n

Sekundaarsed glaukoomivormid<\/strong> v\u00f5ivad kaasneda diabeedi, h\u00fcpertensiooni, katarakti, silma kasvajate v\u00f5i uveiidiga. Levinuim sekundaarne glaukoom on eksfoliatiivne glaukoom<\/strong>.<\/p>","protected":false},"excerpt":{"rendered":"

Glaukoomiga seotud geenide sekveneerimine Geenid: ACVR1, ASB10, BEST1, CANT1, COL18A1, CYP1B1, FOXC1, LMX1B, LOXL1, LTBP2, MYOC, NTF4, OPTN, PAX6, PITX2, PITX3, SBF2, SLC4A4, WDR36 Metoodika: Kodeeriva piirkonna sekveneerimine (NGS). Koopiaarvu muutuste bioinformaatiline anal\u00fc\u00fcs (CNV). CNV leidude kinnitamine teise meetodiga toimub lisaanal\u00fc\u00fcsina, vastavalt hinnakirjale. Testi valmimisaeg: 6-9 n\u00e4dalat N\u00f5uded proovi- materjalile: 2-4 ml t\u00e4isverd antikoagulandiga EDTA […]<\/p>\n","protected":false},"author":2,"featured_media":0,"parent":11406,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"class_list":["post-17586","page","type-page","status-publish","hentry"],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/www.asperbio.com\/et\/wp-json\/wp\/v2\/pages\/17586","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.asperbio.com\/et\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.asperbio.com\/et\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.asperbio.com\/et\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.asperbio.com\/et\/wp-json\/wp\/v2\/comments?post=17586"}],"version-history":[{"count":3,"href":"https:\/\/www.asperbio.com\/et\/wp-json\/wp\/v2\/pages\/17586\/revisions"}],"predecessor-version":[{"id":24423,"href":"https:\/\/www.asperbio.com\/et\/wp-json\/wp\/v2\/pages\/17586\/revisions\/24423"}],"up":[{"embeddable":true,"href":"https:\/\/www.asperbio.com\/et\/wp-json\/wp\/v2\/pages\/11406"}],"wp:attachment":[{"href":"https:\/\/www.asperbio.com\/et\/wp-json\/wp\/v2\/media?parent=17586"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}